The Minnesota Heart Failure Consortium (MHFC), led by faculty from the Division of Cardiology at the University of Minnesota, is comprised of cardiologists and nurses practicing at 10 clinics and hospitals in the greater Twin Cities area. Patient populations at these sites encompass both acute and chronic heart failure at all severity levels, and a wide demographic mix. The MHFC was formed in 2002, has a full time coordinator, and an established record of successful collaborative investigative and educational activity. Leadership and infrastructure are therefore in place to become a successful and productive Regional Clinical Center in the proposed network. Research proposals for the RFA include first a novel study in which the clinical and biological impact of a nondiuretic-based strategy of volume control will be compared with usual care in patients presenting with acute heart failure decompensation. The study will be initiated during hospital admission and continued for 3 months. Ultrafiltration will be used to achieve and maintain volume homeostasis in the nondiuretic group. The primary endpoint of this study is maintenance of stable renal function. Secondary goals include characterization of the relationship between numerous clinical and biological variables and the development of renal insufficiency in the post-discharge period. This study will therefore address several important questions regarding the acute and chronic impact of diuretic therapy on the development of renal dysfunction in patients with ADHF, represent the first chronic trial of a regimen for volume control not based on loop diuretics, and significantly expand the knowledge base regarding the behavior of several key clinical and biological variables on the clinical course of patients presenting with ADHF. The second proposed study involves the first test of the orally effective selective beta-2 adrenergic agonist clenbuterol in patients with moderate to severe, but stable chronic heart failure. The study will access the impact of clenbuterol, a promising agent based on preliminary experience in end-stage patients, on several clinical and biological variables in this population. These proposals therefore deal with timely questions, represent logical extensions of work with which MHFC investigators and sites have already obtained considerable experience, have the potential to either expand our knowledge of the role of existing treatment strategies or to substantially increase information regarding a promising new agent. Protocols to address these issues would be of suitable size for study in protocols of the size envisioned by the proposed network.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL084861-05
Application #
7878707
Study Section
Special Emphasis Panel (ZHL1-CSR-H (M1))
Program Officer
Mascette, Alice
Project Start
2006-09-30
Project End
2012-12-31
Budget Start
2011-01-01
Budget End
2012-12-31
Support Year
5
Fiscal Year
2011
Total Cost
$304,616
Indirect Cost
Name
Minneapolis Medical Research Fdn, Inc.
Department
Type
DUNS #
068195064
City
Minneapolis
State
MN
Country
United States
Zip Code
55415
Vader, Justin M; LaRue, Shane J; Stevens, Susanna R et al. (2016) Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. J Card Fail 22:875-883
AbouEzzeddine, Omar F; Lala, Anuradha; Khazanie, Prateeti P et al. (2016) Evaluation of a provocative dyspnea severity score in acute heart failure. Am Heart J 172:34-41
Wan, Siu-Hin; Stevens, Susanna R; Borlaug, Barry A et al. (2016) Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail 9:
Butler, Javed; Hernandez, Adrian F; Anstrom, Kevin J et al. (2016) Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail 4:726-35
Grodin, Justin L; Stevens, Susanna R; de Las Fuentes, Lisa et al. (2016) Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. J Card Fail 22:26-32
Margulies, Kenneth B; Hernandez, Adrian F; Redfield, Margaret M et al. (2016) Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 316:500-8
AbouEzzeddine, Omar F; Wong, Yee Weng; Mentz, Robert J et al. (2016) Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. J Card Fail 22:853-858
Hussain, Imad; Mohammed, Selma F; Forfia, Paul R et al. (2016) Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Circ Heart Fail 9:e002729
Redfield, Margaret M; Anstrom, Kevin J; Levine, James A et al. (2015) Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 373:2314-24
AbouEzzeddine, Omar F; Haines, Phillip; Stevens, Susanna et al. (2015) Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail 3:245-52

Showing the most recent 10 out of 21 publications